Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Regeneron Pharmaceuticals Inc (REGN) P/E Ratio & Valuation History
Regeneron Pharmaceuticals (REGN) trades at 18.4x trailing earnings and 5.7x sales. Its P/E of 18.4x is above its 5-year median of 16.4x. Its forward P/E is 14.0x. The median P/E across 5 similar companies is 33.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 31.4% higher over the next year. Its free cash flow yield is 4.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 18.4x |
| Forward P/E | 14.0x |
| Price to sales | 5.7x |
| Price to book | 2.9x |
| EV/EBITDA | 15.2x |
| Price to FCF | 25.3x |
| EV/FCF | 24.9x |
| PEG | 1.2 |
| FCF yield | 4.0% |
Historical Medians
Against its 10-year medians, its P/E is 8.9% above 16.9x, its P/S is 10.9% below 6.4x and its P/B is 23.7% below 3.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 18.4x | 16.4x | 16.9x |
| P/S | 5.7x | 5.6x | 6.4x |
| P/B | 2.9x | 3.3x | 3.8x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 8.4x in 2021 to 31.8x in 2016.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $771.87 | 17.4x | 5.7x | 2.7x |
| 2024 | $712.33 | 15.6x | 5.5x | 2.8x |
| 2023 | $878.29 | 20.1x | 7.3x | 3.8x |
| 2022 | $721.49 | 16.0x | 6.5x | 3.6x |
| 2021 | $631.52 | 8.4x | 4.2x | 3.8x |
| 2020 | $483.11 | 15.3x | 6.2x | 4.9x |
| 2019 | $375.48 | 15.2x | 6.3x | 3.9x |
| 2018 | $373.50 | 16.4x | 7.9x | 4.9x |
| 2017 | $375.96 | 23.1x | 7.0x | 7.1x |
| 2016 | $367.09 | 31.8x | 8.1x | 9.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About REGN
What is REGN's forward P/E ratio?
Regeneron Pharmaceuticals has a forward P/E ratio of 14.0x.
Is REGN stock overvalued?
GNG's valuation label for REGN is Undervalued. Its P/E of 18.4x compares with a median of 33.5x across 5 similar companies.
What is REGN's price to sales ratio?
Regeneron Pharmaceuticals has a price to sales ratio of 5.7x.
What is Regeneron Pharmaceuticals's average P/E ratio over 5 years?
Regeneron Pharmaceuticals's median P/E over the last 5 years is 16.4x, from 60 month-end values through Oct 2026.
What is REGN's PEG ratio?
Regeneron Pharmaceuticals has a PEG ratio of 1.2.
REGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts